Figure 2.

DC101 therapy delays tumor growth and severely impairs vascularization in EAC tumors. (A) Nude mice bearing subcutaneous EAC-derived xenografts of 50–75 mm³ were treated with 40 mg/kg DC101 or PBS control therapy twice a week for four weeks. Tumor size was normalized against tumor size at the start of the treatment (day 0). (B) Percent survival of mice after DC101 or control therapy expressed using Kaplan–Meier curves. Log-rank (Mantel–Cox) test was used to determine statistical significance. (C) DC101 treated and control tumors were immunohistochemically stained for CD31 antibody to determine vascularization. (D) Quantification of CD31 staining of tumor sections using ImageJ software as percentage of area. Line graphs and scatter dot plots show the mean ± SD, n = 5 per group. **p < .01 was determined by two-sided unpaired t-tests and analyzed against untreated control.